C-Src dependency of NSAID-induced effects on NF-κB-mediated apoptosis in colorectal cancer cells

Carcinogenesis

Volumn 32, Issue 7, 2011, Pages 1069-1077

  Brady, Richard R W ^a   Loveridge, Carolyn J ^a   Dunlop, Malcolm G ^a   Stark, Lesley A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; SULINDAC SULFONE;

APOPTOSIS; ARTICLE; CANCER CELL; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 79960054906     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr077     Document Type: Article

References (51)

1. Parkin, D.M. (2001) Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-543.
2. Ferlay, J. et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int. J. Cancer, 127, 2893-2917.
3. Gondos, A. et al. (2009) Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann. Oncol., 20, 564-573.
4. Flossmann, E. et al. (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet, 369, 1603-1613.
5. Rostom, A. et al. (2007) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann. Intern. Med., 146, 376-389.
6. Dubé, C. et al. (2007) The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann. Intern. Med., 146, 365-375.
7. Din, F.V. et al. (2010) Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut., 59, 1670-1679.
8. Yamamoto, Y. et al. (1999) Sulindac inhibits activation of the NF-kappaB pathway. J. Biol. Chem., 274, 27307-27314.
9. Stark, L.A. et al. (2001) Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J., 15, 1273-1275.
10. Karin, M. et al. (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol., 18, 621-663.
11. Perkins, N.D. (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol., 8, 49-62.
12. Basse'res, D.S. et al. (2006) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene, 25, 6817-6830.
13. Bharti, A.C. et al. (2002) Chemopreventive agents induce suppression of nuclear factor-kappaB leading to chemosensitization. Ann. N. Y. Acad. Sci., 973, 392-395.
14. Din, F.V. et al. (2004) Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br. J. Cancer, 91, 381-388.
15. Stark, L.A. et al. (2007) Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis, 28, 968-976.
16. Loveridge, C.J. et al. (2008) The proapoptotic effects of sulindac, sulindac Sulphone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. Oncogene, 27, 2648-2655.
17. Thoms, H.C. et al. (2007) p38-mediated inactivation of cyclin D1/cyclindependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells. Cancer Res., 67, 1660-1669.
18. Talamonti, M.S. et al. (1993) Increase in activity and level of pp.60c-src in progressive stages of human colorectal cancer. J. Clin. Invest., 91, 53-60.
19. Mao, W. et al. (1997) Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene, 15, 3083-3090.
20. Termuhlen, P.M. et al. (1993) Site-specific differences in pp.60c-src activity in human colorectal metastases. J. Surg. Res., 54, 293-298.
21. Kang, J.L. et al. (2006) Src tyrosine kinases mediate crystalline silicainduced NF-kappaB activation through tyrosine phosphorylation of IkappaB-alpha and p65 NF-kappaB in RAW 264.7 macrophages. Toxicol. Sci., 90, 470-477.
22. Kang, J.L. et al. (2005) Inhibition of SRC tyrosine kinases suppresses activation of nuclear factor-kappaB, and serine and tyrosine phosphorylation of IkappaB-alpha in lipopolysaccharide-stimulated raw 264.7 macrophages. J. Toxicol. Environ. Health A, 68, 1643-1662.
23. Fan, C. et al. (2003) Tyrosine phosphorylation of I kappa B alpha activates NF kappa B through a redox-regulated and c-Src-dependent mechanism following hypoxia/reoxygenation. J. Biol. Chem., 278, 2072-2080.
24. Lluis, J.M. et al. (2007) Dual role of mitochondrial reactive oxygen species in hypoxia signaling: activation of nuclear factor-{kappa}B via c-SRC and oxidant-dependent cell death. Cancer Res., 67, 7368-7377.
25. Chang, Y.J. et al. (2004) Induction of cyclooxygenase-2 overexpression in human gastric epithelial cells by Helicobacter pylori involves TLR2/TLR9 and c-Src-dependent nuclear factor-kappaB activation. Mol. Pharmacol., 66, 1465-1477.
26. Méndez-Samperio, P. et al. (2007) Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced CXCL8 production is mediated through PKCalpha-dependent activation of the IKKalphabeta signaling pathway in epithelial cells. Cell Immunol., 245, 111-118.
27. Funakoshi-Tago, M. et al. (2005) Functional role of c-Src in IL-1-induced NF-kappa B activation: c-Src is a component of the IKK complex. J. Biochem., 137, 189-197.
28. Huang, W.C. et al. (2003) c-Src-dependent tyrosine phosphorylation of IKKbeta is involved in tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 expression. J. Biol. Chem., 278, 9944-9952.
29. Lin, C.H. et al. (2006) c-Src mediates thrombin-induced NF-kappaB activation and IL-8/CXCL8 expression in lung epithelial cells. J. Immunol., 177, 3427-3438.
30. Baek, J.E. et al. (2010) Fatty acid-bearing albumin induces VCAM-1 expression through c-Src kinase-AP-1/NF-kB pathways: effect of L-carnitine. Kidney Blood Press. Res., 33, 72-84.
31. Wang, Z. et al. (2001) Salicylate inhibits phosphorylation of the nonreceptor tyrosine kinases, proline-rich tyrosine kinase 2 and c-Src. Hypertension, 37, 148-153.
32. Ramdas, L. et al. (1998) The instability of polyhydroxylated aromatic protein tyrosine kinase inhibitors in the presence of manganese. Cancer Biochem. Biophys., 16, 375-385.
33. Jalal, D.I. et al. (2006) Src activation of NF-kappaB augments IL-1betainduced nitric oxide production in mesangial cells. J. Am. Soc. Nephrol., 17, 99-106.
34. Perez-G, M. et al. (2002) Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. J. Immunol., 168, 1428-1434.
35. Stark, L.A. et al. (2005) Nucleolar sequestration of RelA (p65) regulates NF-kappaB-driven transcription and apoptosis. Mol. Cell. Biol., 25, 5985-6004.
36. Roskoski, R. (2004) Src protein-tyrosine kinase structure and regulation. Biochem. Biophys. Res. Commun., 324, 1155-1164.
37. Sachdev, S. et al. (2009) Paxillin-Y118 phosphorylation contributes to the control of Src-induced anchorage-independent growth by FAK and adhesion. BMC Cancer, 9, 12.
38. Nam, J.S. et al. (2002) Src family kinase inhibitor PP2 restores the Ecadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res., 8, 2430-2436.
39. Blake, R.A. et al. (2000) SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol. Cell. Biol., 20, 9018-9027.
40. Kunte, D.P. et al. (2008) Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase. Mol. Cancer Ther., 7, 1797-1806.
41. Casanova, I. et al. (2006) Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas. Int. J. Cancer, 118, 2381-2389.
42. Grosjean, J. et al. (2006) Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFkappaB. Biochem. Biophys. Res. Commun., 340, 984-994.
43. Imbert, V. et al. (1996) Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell, 86, 787-798.
44. Koong, A.C. et al. (1994) Hypoxic activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Res., 54, 5273-5279.
45. Elder, D.J. et al. (2002) The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int. J. Cancer, 99, 323-327.
46. Bernardi, A. et al. (2006) Nonsteroidal anti-inflammatory drugs inhibit the growth of C6 and U138-MG glioma cell lines. Eur. J. Pharmacol., 532, 214-222.
47. Welman, A. et al. (2006) Increases in c-Src expression level and activity do not promote the growth of human colorectal carcinoma cells in vitro and in vivo. Neoplasia, 8, 905-916.
48. Zhong, M. et al. (2002) Downregulating PKC delta provides a PI3K/Aktindependent survival signal that overcomes apoptotic signals generated by c-Src overexpression. Oncogene, 21, 1071-1078.
49. Vidal, M. et al. (2007) Differing Src signaling levels have distinct outcomes in Drosophila. Cancer Res., 67, 10278-10285.
50. Webb, B.L. et al. (2000) v-Src generates a p53-independent apoptotic signal. Mol. Cell. Biol., 20, 9271-9280.
51. Lu, X. et al. (1997) NSAID-induced apoptosis in Rous sarcoma virustransformed chicken embryo fibroblasts is dependent on v-src and c-myc and is inhibited by bcl-2. Prostaglandins, 54, 549-568. sadam3